Metastatic Pancreatic Cancer Clinical Trial
Official title:
Spleen Irradiation With Nanoliposomal Irinotecan Plus 5-FU and Leucovorin in Metastatic Pancreatic Adenocarcinoma: a Phase II Study (SINAI)
Splenomegaly is common in advanced pancreatic ductal adenocarcinoma (PDAC). The spleen is an important source of immune suppressive cells and phagocytic cells and may mediate the accumulation of liposomal drugs and immunosuppression. In this study, spleen irradiation (SI) will be added to standard chemotherapy.
Splenomegaly is common in PDAC. Therefore, we design a phase II study to enroll metastatic PDAC patients who have failed prior gemcitabine-based therapy and have splenomegaly. With add-on SI to standard nal-IRI/FL therapy, we hypothesize that 1) splenic phagocytes and spleen volume will be reduced with attenuated entrapment of nal-IRI within spleen, 2) splenic source of immunosuppressive immune cells will be reduced with potential reconstitution of antitumor TME. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04753879 -
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
|
Phase 2 | |
| Completed |
NCT01417000 -
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT02975141 -
Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT00761345 -
Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer
|
Phase 1 | |
| Completed |
NCT00919282 -
Gemcitabine (GFF) in Patients With Pancreatic Cancer
|
Phase 2 | |
| Completed |
NCT01088815 -
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
|
Phase 2 | |
| Completed |
NCT04133155 -
Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer
|
||
| Withdrawn |
NCT05251038 -
Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04612530 -
PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer
|
Phase 1 | |
| Completed |
NCT03602885 -
EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options
|
N/A | |
| Recruiting |
NCT05442749 -
Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT04222413 -
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT03721744 -
A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer
|
Phase 2/Phase 3 | |
| Completed |
NCT03261947 -
A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
|
Phase 2 | |
| Withdrawn |
NCT06017323 -
Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal Adenocarcinoma
|
Phase 1 | |
| Terminated |
NCT01946646 -
Phase I Study of TS-1 With Concurrent Radiotherapy to Treat Pancreatic Cancer
|
Phase 1 | |
| Completed |
NCT01523457 -
Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT00986661 -
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
|
Phase 1 | |
| Terminated |
NCT00726037 -
A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer
|
Phase 2 | |
| Completed |
NCT00744640 -
Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma
|
Phase 1/Phase 2 |